To verify our hypothesis, we treated an LKB1 wild-type lung cancer cell line H358, and three LKB1 deficient lung cancer cell lines, H838, H1355, and H1993 (Figure 6C), with 6(5H)-phenanthridinone (PHEN), a PARP-1 inhibitor. Here, PARP1 is linked to lung carcinoma.